Carolina Cruz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carolina Cruz has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Till Bruckner
UiT The Arctic University of Norway
3 shared publications - Martin Ringsten
Department of Health Sciences, Lund University , Lund
2 shared publications Aminul Schuster
University of Westminster, London
1 shared publication- Belen Chavarria
National Autonomous University of Nicaragua at León
1 shared publication - Christie Ebube Dike
Independent Researcher, Ibadan, Nigeria
1 shared publication - Daniel Sanchez
Universidad de Guadalajara, Guadalajara, Jalisco
1 shared publication
Latest Publications
- Open Access
- 1 May 2024
- Published by F1000 Research Ltd in F1000Research
- Vol. 13, 431
Regulatory gaps and research waste in clinical trials involving women with metastatic breast cancer in Germany
Background Non-publication, incomplete publication and excessively slow publication of clinical trial outcomes contribute to research waste and can harm patients. While research waste in German academic trials is well documented, research waste in Germany related to a specific disease area across non-commercial and commercial sponsors has not previously been assessed. Methods In this cohort study, we used public records from three clinical trial registries to identify 70 completed or terminated clinical trials involving women with metastatic breast cancer with trial sites in Germany. We then searched registries and the literature for trial outcomes and contacted sponsors about unreported studies. Results We found that 66/70 trials (94.3%) had made their results public. Only 13/70 (18.6%) trials had reported results within one year of completion as recommended by the World Health Organisation (WHO). The outcomes of 4/70 trials (5.7%) had not been made public at all, but only one of those trials had recruited a significant number of patients. Conclusions Discussions about research waste in clinical trials commonly focus on weakly designed or unreported trials. We believe that late reporting of results is another important form of research waste. In addition, a discussion regarding the appropriate ethical and legal rules for reporting the results of terminated trials might add value. German legislation now requires sponsors to upload the results of some clinical trials onto a trial registry within one year of trial completion, but these laws only cover around half of all trials. Our findings highlight the potential benefits of extending the scope of national legislation to cover all interventional clinical trials involving German patients.
- 1 May 2024
- Published by F1000 Research Ltd in F1000Research
- Vol. 13, 431
Open AccessRegulatory gaps and research waste in clinical trials involving women with metastatic breast cancer in Germany
Background Non-publication, incomplete publication and excessively slow publication of clinical trial outcomes contribute to research waste and can harm patients. While research waste in German academic trials is well documented, research waste in Germany related to a specific disease area across non-commercial and commercial sponsors has not previously been assessed. Methods In this cohort study, we used public records from three clinical trial registries to identify 70 completed or terminated clinical trials involving women with metastatic breast cancer with trial sites in Germany. We then searched registries and the literature for trial outcomes and contacted sponsors about unreported studies. Results We found that 66/70 trials (94.3%) had made their results public. Only 13/70 (18.6%) trials had reported results within one year of completion as recommended by the World Health Organisation (WHO). The outcomes of 4/70 trials (5.7%) had not been made public at all, but only one of those trials had recruited a significant number of patients. Conclusions Discussions about research waste in clinical trials commonly focus on weakly designed or unreported trials. We believe that late reporting of results is another important form of research waste. In addition, a discussion regarding the appropriate ethical and legal rules for reporting the results of terminated trials might add value. German legislation now requires sponsors to upload the results of some clinical trials onto a trial registry within one year of trial completion, but these laws only cover around half of all trials. Our findings highlight the potential benefits of extending the scope of national legislation to cover all interventional clinical trials involving German patients.
- Open Access
Publication status and disclosure gaps in a cohort of 71 clinical trials assessing the safety and efficacy of 3 COVID-19 vaccines developed by Chinese biopharmaceutical companies: An observational cohort study
Transparency shortcomings can undermine confidence in the safety and efficacy of vaccines. This study assesses the publication status and disclosure gaps in a cohort of 71 clinical trials assessing the safety and efficacy of 3 COVID-19 vaccines developed by Chinese biopharmaceutical companies that received a World Health Organization Emergency Use Listing (EUL) and have been marketed globally. We searched trial registries and the scientific literature to assess the completion status of those 71 trials, and to determine whether the outcomes of completed trials have been made publicly available. The 71 trials in our cohort were initiated by sponsors headquartered in 17 different countries and aimed to enrol a total of 313,750 participants from across 27 countries. Out of those 71 trials, 49 trials (69%) had verifiably been concluded. We were unable to determine the completion status of the remaining 22 trials (31%) with certainty. Depending on whether those 22 trials were assumed to have been concluded or not, we found that between 13 completed trials (27%) and 35 completed trials (49%) remained unreported. At least 9 trials (13% of the total) had not made their results public more than one year post completion. According to registry data, between 36,498 people (12% of participants across all trials) and 89,224 people (28%) had participated in trials that had been concluded and whose outcomes remained unreported. There were no tabular summary results available on trial registries for any of the trials. Our findings suggest that there are significant gaps in clinical trial governance, especially in countries that have only recently emerged as significant players in biomedical research. Maintaining global progress in clinical trial reporting will require legislators and regulators to adopt and effectively enforce clinical trial reporting requirements that reflect WHO best practices. The global clinical trial registry infrastructure needs to be strengthened so that users can reliably determine whether studies have been withdrawn, are still ongoing, or have been concluded. Key messages: What is already known on this topic: The results of many clinical trials are only made public partially, after long delays, or not at all. Such disclosure gaps can make it difficult to assess the benefits and harms of treatments, and can undermine public trust in health interventions, including vaccines. In North America and Europe, disclosure has significantly improved in recent years. What this study adds: Previous research in this field has overwhelmingly focused on clinical trials run by sponsors in North America and Europe that usually involved patients in these regions. Our study provides a global perspective on the problem, using a cohort of trials with high salience for global public health. More than 1.3 billion doses of 3 COVID-19 vaccines originally developed in China have been exported to dozens of countries worldwide. We assessed the publication status and disclosure gaps of 71 clinical trials of these vaccines. We found widespread research activity in newly emerging hubs of biomedical innovation. In total, sponsors from 17 different countries and participants from 27 countries were involved in relevant trials. None of the concluded trials had reported outcomes in line with global best practice standards set out by the World Health Organisation. How this study might affect research, practice or policy: Clinical trial activity is increasingly becoming global. Our research points to significant gaps in clinical trial governance in many emerging hubs of biomedical innovation. Legislators and regulators in these countries should ensure that all clinical trial results are rapidly made public in line with World Health Organisation best practices to prevent the growth of gaps in the global medical evidence base. In addition, there is an urgent need to strengthen the global clinical trial registry infrastructure.
Open AccessPublication status and disclosure gaps in a cohort of 71 clinical trials assessing the safety and efficacy of 3 COVID-19 vaccines developed by Chinese biopharmaceutical companies: An observational cohort study
Transparency shortcomings can undermine confidence in the safety and efficacy of vaccines. This study assesses the publication status and disclosure gaps in a cohort of 71 clinical trials assessing the safety and efficacy of 3 COVID-19 vaccines developed by Chinese biopharmaceutical companies that received a World Health Organization Emergency Use Listing (EUL) and have been marketed globally. We searched trial registries and the scientific literature to assess the completion status of those 71 trials, and to determine whether the outcomes of completed trials have been made publicly available. The 71 trials in our cohort were initiated by sponsors headquartered in 17 different countries and aimed to enrol a total of 313,750 participants from across 27 countries. Out of those 71 trials, 49 trials (69%) had verifiably been concluded. We were unable to determine the completion status of the remaining 22 trials (31%) with certainty. Depending on whether those 22 trials were assumed to have been concluded or not, we found that between 13 completed trials (27%) and 35 completed trials (49%) remained unreported. At least 9 trials (13% of the total) had not made their results public more than one year post completion. According to registry data, between 36,498 people (12% of participants across all trials) and 89,224 people (28%) had participated in trials that had been concluded and whose outcomes remained unreported. There were no tabular summary results available on trial registries for any of the trials. Our findings suggest that there are significant gaps in clinical trial governance, especially in countries that have only recently emerged as significant players in biomedical research. Maintaining global progress in clinical trial reporting will require legislators and regulators to adopt and effectively enforce clinical trial reporting requirements that reflect WHO best practices. The global clinical trial registry infrastructure needs to be strengthened so that users can reliably determine whether studies have been withdrawn, are still ongoing, or have been concluded. Key messages: What is already known on this topic: The results of many clinical trials are only made public partially, after long delays, or not at all. Such disclosure gaps can make it difficult to assess the benefits and harms of treatments, and can undermine public trust in health interventions, including vaccines. In North America and Europe, disclosure has significantly improved in recent years. What this study adds: Previous research in this field has overwhelmingly focused on clinical trials run by sponsors in North America and Europe that usually involved patients in these regions. Our study provides a global perspective on the problem, using a cohort of trials with high salience for global public health. More than 1.3 billion doses of 3 COVID-19 vaccines originally developed in China have been exported to dozens of countries worldwide. We assessed the publication status and disclosure gaps of 71 clinical trials of these vaccines. We found widespread research activity in newly emerging hubs of biomedical innovation. In total, sponsors from 17 different countries and participants from 27 countries were involved in relevant trials. None of the concluded trials had reported outcomes in line with global best practice standards set out by the World Health Organisation. How this study might affect research, practice or policy: Clinical trial activity is increasingly becoming global. Our research points to significant gaps in clinical trial governance in many emerging hubs of biomedical innovation. Legislators and regulators in these countries should ensure that all clinical trial results are rapidly made public in line with World Health Organisation best practices to prevent the growth of gaps in the global medical evidence base. In addition, there is an urgent need to strengthen the global clinical trial registry infrastructure.
- Open Access
Are European Clinical Trial Funders Policies on Clinical Trial Registration and Reporting Improving? – A Cross-Sectional Study
Objectives Assess the extent to which the clinical trial registration and reporting policies of 25 of the world’s largest public and philanthropic medical research funders meet best practice benchmarks as stipulated by the 2017 WHO Joint Statement,(1) and document changes in the policies and monitoring systems of 19 European funders over the past year. Design, Setting, Participants Cross sectional study, based on assessments of each funder’s publicly available documentation plus validation of results by funders. Our cohort includes the 25 of the largest public and philanthropic medical research funders in Europe, Oceania, South Asia and Canada. Of these, 19 were previously assessed against the same benchmarks, enabling us to document changes over time. Interventions Scoring of all 25 funders using an 11-item assessment tool based on WHO best practice benchmarks, grouped into 3 primary categories: trial registries, academic publication and monitoring, plus validation of results by funders. Main outcome measures The primary outcome measure is how many of the 11 WHO best practice items each of the 25 funders has put into place, and changes in the performance of 19 previously assessed funders over the preceding year. Results The 25 funders we assessed had put into place an average of 5/11 (49%) WHO best practices. The best practice adopted by most funders 16/25 (64%) was mandating open access publication in journals. In contrast, only 6/25 funders (24%) took PI’s past reporting record into account during grant application reviews. Funders’ performance varied widely from 0/11 to 11/11 WHO best practices adopted. Of the 19 funders for which 2021 baseline data were available,(2) 10/19 (53%) had strengthened their policies over the preceding year. Conclusions Most medical research funders need to do more to curb research waste and publication bias by strengthening their clinical trial policies. Key Points WHAT IS ALREADY KNOWN ABOUT THIS TOPIC Key PointsStrong clinical trial registration and reporting policies coupled with monitoring and sanctions can reduce research waste, curb publication bias and promote transparency. A 2021 assessment found that 19 European medical research funders’ policies fell short of WHO best practices. WHAT THIS STUDY ADDS This is the first study to assess the clinical trial registration and reporting policies of a global cohort of 25 major medical research funders against WHO best practices, identifying gaps in the research waste safeguards of key players across Europe, Oceania, South Asia and Canada. In addition, the study assesses the progress made by 19 funders in the recent past. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY This study enables funders worldwide to identify and address gaps in their clinical trial transparency policies by pinpointing exactly where they currently fall short of WHO best practices. It also enables policy makers and citizens to assess whether public bodies tasked with furthering medical knowledge have adopted adequate safeguards against research waste and publication bias.
Open AccessAre European Clinical Trial Funders Policies on Clinical Trial Registration and Reporting Improving? – A Cross-Sectional Study
Objectives Assess the extent to which the clinical trial registration and reporting policies of 25 of the world’s largest public and philanthropic medical research funders meet best practice benchmarks as stipulated by the 2017 WHO Joint Statement,(1) and document changes in the policies and monitoring systems of 19 European funders over the past year. Design, Setting, Participants Cross sectional study, based on assessments of each funder’s publicly available documentation plus validation of results by funders. Our cohort includes the 25 of the largest public and philanthropic medical research funders in Europe, Oceania, South Asia and Canada. Of these, 19 were previously assessed against the same benchmarks, enabling us to document changes over time. Interventions Scoring of all 25 funders using an 11-item assessment tool based on WHO best practice benchmarks, grouped into 3 primary categories: trial registries, academic publication and monitoring, plus validation of results by funders. Main outcome measures The primary outcome measure is how many of the 11 WHO best practice items each of the 25 funders has put into place, and changes in the performance of 19 previously assessed funders over the preceding year. Results The 25 funders we assessed had put into place an average of 5/11 (49%) WHO best practices. The best practice adopted by most funders 16/25 (64%) was mandating open access publication in journals. In contrast, only 6/25 funders (24%) took PI’s past reporting record into account during grant application reviews. Funders’ performance varied widely from 0/11 to 11/11 WHO best practices adopted. Of the 19 funders for which 2021 baseline data were available,(2) 10/19 (53%) had strengthened their policies over the preceding year. Conclusions Most medical research funders need to do more to curb research waste and publication bias by strengthening their clinical trial policies. Key Points WHAT IS ALREADY KNOWN ABOUT THIS TOPIC Key PointsStrong clinical trial registration and reporting policies coupled with monitoring and sanctions can reduce research waste, curb publication bias and promote transparency. A 2021 assessment found that 19 European medical research funders’ policies fell short of WHO best practices. WHAT THIS STUDY ADDS This is the first study to assess the clinical trial registration and reporting policies of a global cohort of 25 major medical research funders against WHO best practices, identifying gaps in the research waste safeguards of key players across Europe, Oceania, South Asia and Canada. In addition, the study assesses the progress made by 19 funders in the recent past. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY This study enables funders worldwide to identify and address gaps in their clinical trial transparency policies by pinpointing exactly where they currently fall short of WHO best practices. It also enables policy makers and citizens to assess whether public bodies tasked with furthering medical knowledge have adopted adequate safeguards against research waste and publication bias.